Information  X 
Enter a valid email address

Shield Therapeutics (STX)

  Print   

Friday 18 June, 2021

Shield Therapeutics

Directorate Change

RNS Number : 2986C
Shield Therapeutics PLC
18 June 2021
 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Directorate Change

 

London, UK, 18 June 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that further to the announcement issued on 28 May 2021, Greg Madison will join the Board with immediate effect and is fulfilling the role of the Group's Chief Executive Officer.

 

Shield also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies.

 

Full name: Gregory Paul Madison

 

Age: 53 years

 

Current directorships/partnerships:

· American Kidney Fund, Board of Trustees 

 

Previous directorships/partnerships held in the past 5 years:

· Melt Pharmaceuticals, Inc.

· Keryx Biopharmaceuticals, Inc.

· Keryx Biopharma UK Ltd.

 

Mr Madison currently does not hold any ordinary shares in Shield.

 

There are no other disclosures required in connection with the appointment of Mr Madison under Schedule Two(g) of the Aim Rules for Companies.

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

+44 (0) 191 511 8500

Lucy Huntington-Bailey


 

Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel/Christopher Golden

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd 

Geoff Nash/Alice Lane/George Dollemore 

 

 

+44 (0)20 7220 0500



 

Financial PR & IR Advisor

 

Walbrook PR

+44 (0)20 7933 8780 or  [email protected]

Paul McManus/Lianne Cawthorne


 

 

 

 

 

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAMZGMVKNLGMZM

a d v e r t i s e m e n t